Back to discover
Drug

Bimatoprost

Established medicine
ClassProstanoid FP receptor agonistResearchOngoing clinical research
Also known as Bimatoprost Topical, Durysta, Latisse, Lumigan+3 more

Bimatoprost Topical, Durysta, Latisse, Lumigan, Zolymbus, (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide, Bimatoprostum.

RxNorm283810ChEMBLCHEMBL1200963ATCS01EE03UNIIQXS94885MZ
1
Active clinical trials
Prostaglandin F2-alpha receptor
Primary target
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Clinical trial2026-05-22Results expected Q2 2029 · ClinicalTrials.gov

A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Clinical trial2025-08-08Completed · ClinicalTrials.gov

Evaluation of Laser-assisted Drug Delivery of Bimatoprost for the Treatment of Hypertrophic Scar Hypopigmentation: A Within Patient-Controlled Trial in Skin of Color

Clinical trial2024-12-30Primary completion · ClinicalTrials.gov

Stop Retinal Ganglion Cell Dysfunction Study

Clinical trial2024-10-04Terminated · ClinicalTrials.gov

Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients

Clinical trial2023-11-21Results posted · ClinicalTrials.gov

An Evaluation of the 24-Hour Intraocular Pressure(IOP)-Lowering Effect of Bimatoprost Sustained-Release(SR) in Participants With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)

Clinical trial2023-06-08Results posted · ClinicalTrials.gov

A Proof of Concept, Split Study Measuring the Effectiveness of Topical ProstaglandinF2alpha, Microneedling and Excimer Laser in the Treatment of Vitiligo

Clinical trial2022-05-15Completed · ClinicalTrials.gov

A Phase 2 Prospective, Multicenter, Randomized, Double-masked, Controlled Study to Evaluate the Efficacy and Safety and Dose-response of the Bimatoprost Ocular Insert (2.2 mg, 13 mg) With and Without Concomitant Artificial Tears Compared to a Placebo Ocular Insert With and Without Concomitant Timolol (0.5%) Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

Clinical trial2020-06-04Results posted · ClinicalTrials.gov

A Multi-Center, Evaluator -Masked, Randomized, Parallel Group, Active Controlled, Comparative Study of SPARC's SDP-133 Once Daily Compared With Lumigan ® 0.01% (Bimatoprost Ophthalmic Solution) in Subjects With Open Angle Glaucoma or Ocular Hypertension

Clinical trial2019-07-08Withdrawn · ClinicalTrials.gov

A Phase IIa Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Bimatoprost in the Treatment of Migraine

Clinical trial2019-04-25Primary completion · ClinicalTrials.gov

Bimatoprost for the Treatment of Eyebrow Hypotrichosis

Clinical trial2019-04-23Results posted · ClinicalTrials.gov

Marketing authorisation: Lumigan (EMA)

Regulatory2002-03-08EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Bimatoprost
Aliases & brands
Bimatoprost TopicalDurystaLatisseLumiganZolymbus(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamideBimatoprostum
RxNorm CUI
283810
ChEMBL ID
CHEMBL1200963
ATC codes
S01EE03
UNII
QXS94885MZ
Primary mechanism
Prostanoid FP receptor agonist
Regulatory jurisdictions
ema

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Prostaglandin F2-alpha receptor
PTGFR · P43088
AGONISTProstanoid FP receptor agonist

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2002-03-08
Latest approval
2002-03-08
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2002-03-08Original application approval
Marketing authorisation: Lumigan (EMA)

Indication: Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

25 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
25
registered trials across all phases
LATEST COMPLETION 2025
1
Active studies
13
Late-stage (III+)
19
Completed
5
Discontinued
PHASE DISTRIBUTIONn = 25
Early Phase 11Phase 11Phase 1 / 22Phase 28Phase 2 / 31Phase 37Phase 44Phase N / A1

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Prostaglandin F2-alpha Eye Drops (Bimatoprost) in Thyroid Eye Disease: a Randomised Controlled Double Blind Crossover Trial

CompletedPH IVCardiff Universityn=312016

The Effects of Latanoprost, Bimatoprost and Travoprost on Periocular Skin Pigmentation

CompletedPH IVSumma Health Systemn=892011

A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension

CompletedPH IVInnovative Medical2007

The 24 Control of IOP in Ocular Hypertension: a Cross-over Study on Inflow Versus Outflow Drugs.

CompletedPH IVUniversity of Parman=612004

A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

CompletedPH IIIAbbVien=5152025

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

CompletedPH IIIAbbVien=5152025

A Proof of Concept, Split Study Measuring the Effectiveness of Topical ProstaglandinF2alpha, Microneedling and Excimer Laser in the Treatment of Vitiligo

CompletedPH IMedical University of South Carolinan=42022

An Evaluation of the 24-Hour Intraocular Pressure(IOP)-Lowering Effect of Bimatoprost Sustained-Release(SR) in Participants With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)

CompletedPH IIIAbbVien=372022

Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients

CompletedPH IIILaboratoires Thean=4852021

A Phase 1B, Multicenter, Randomized, Double-masked, Controlled Study to Evaluate the Efficacy and Safety of a Fixed Combination Bimatoprost/Timolol Ocular Insert Compared to Its Individual Components With Crossover to Timolol 0.5% in Subjects With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

CompletedPH I/IIForSight Vision5, Inc.n=552016

An Open-label Extension (OLE 2) Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert in Subjects With Open-angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-004

CompletedPH IIForSight Vision5, Inc.n=812016
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.